Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study

Xuejiao Yin1, Lei Chen1, Fengjuan Fan1

  • 1Tongji Medical College, Institute of Hematology, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Oncology
|October 5, 2020
PubMed

Insights

Waldenström macroglobulinemia (WM) incidence and mortality increased, but the rate of increase slowed around 1993. Survival rates have dramatically improved, suggesting better healthcare delivery and research for WM patients.

Area of Science:

  • Hematology
  • Epidemiology
  • Oncology

Background:

  • Waldenström macroglobulinemia (WM) incidence has risen in the US.
  • The relationship between increasing WM incidence and mortality trends remains unclear.

Purpose of the Study:

  • To analyze incidence and mortality trends of WM in the US.
  • To investigate demographic variations in WM incidence and mortality.

Main Methods:

  • Utilized the SEER database (1980-2016) for incidence and mortality data.
  • Employed joinpoint regression to analyze secular trends by demographic characteristics.

Main Results:

  • WM incidence rapidly increased (1980-1993) then stabilized (1993-2016).
  • WM incidence-based mortality (IBM) decreased around 1994, mirroring incidence trends.
  • Significant differences in incidence and mortality trends were observed across various demographic factors.
  • Five-year survival rates dramatically increased from 47.84% to 69.41%.

Conclusions:

  • Both WM incidence and IBM increased, but the rate of increase slowed post-1993.
  • Advances in healthcare and research are crucial for reducing WM mortality.
  • Findings can guide future WM therapy monitoring and research.